Irving Ayala-Rodriguez, MD
Family Practice · Bakersfield
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 12 years
- Graduated 2014
Offices
2 locations · Clinica Sierra Vista · 180 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ayala-Rodriguez’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A159093 · Current
Licensed to practise in California · since 2018 · expires 2028-10-31 · Autonomous University of Guadalajara Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Family Medicine - Family Medicine
Medicaid work
$7,668 in 2024
Medicaid paid $7,668 for 141 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 43 | $5,098 |
| Short return visit (20+ min) | 16 | $1,312 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 13 | $667 |
| Short return visit | 13 | $591 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 41 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 15 | $0 |
| 2024 | 141 | 6 | 16 | $7,668 |
| 2023 | 1,210 | 4 | 92 | $62,551 |
| 2022 | 15,993 | 32 | 857 | $952,557 |
| 2021 | 29,339 | 46 | 753 | $1,834,117 |
| 2020 | 7,144 | 29 | 355 | $417,876 |
| 2019 | 267 | 11 | 44 | $4,106 |
See the largest Medicaid services in earlier years
2023
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 582 | $29,862 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 503 | $20,658 |
| Clinic visit/encounter, all-inclusive | 59 | $10,325 |
| Short return visit (20+ min) | 66 | $1,705 |
2022
| Clinic visit/encounter, all-inclusive | 4,660 | $878,552 |
| Short return visit (20+ min) | 4,828 | $32,245 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 1,031 | $26,135 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 246 | $4,254 |
| Return visit (30+ min) | 437 | $2,920 |
| New patient visit (30+ min) | 277 | $2,259 |
| Short return visit | 402 | $1,428 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 37 | $1,206 |
| OFF/OP EST MAY X REQ PHY/QHP | 46 | $712 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 15 | $535 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 700 | $532 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 32 | $357 |
2021
| Clinic visit/encounter, all-inclusive | 8,614 | $1,623,565 |
| Short return visit (20+ min) | 8,917 | $69,735 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 2,662 | $66,106 |
| Return visit (30+ min) | 1,420 | $17,640 |
| New patient visit (30+ min) | 582 | $14,633 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) | 221 | $7,457 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 109 | $6,060 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 89 | $4,135 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 265 | $3,453 |
| Short return visit | 649 | $3,076 |
| Hemoglobin A1C level | 368 | $2,617 |
| OFF/OP EST MAY X REQ PHY/QHP | 194 | $2,567 |
2020
| Clinic visit/encounter, all-inclusive | 1,897 | $342,738 |
| Short return visit (20+ min) | 1,890 | $27,541 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 333 | $10,785 |
| Short return visit | 992 | $8,724 |
| Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | 96 | $5,771 |
| New patient visit (30+ min) | 124 | $5,390 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 84 | $3,334 |
| Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use | 55 | $2,351 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 162 | $2,332 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 68 | $1,867 |
| GENERAL HEALTH PANEL | 36 | $1,567 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 38 | $650 |
2019
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 39 | $790 |
| GENERAL HEALTH PANEL | 18 | $783 |
| Blood test, lipids (cholesterol and triglycerides) | 59 | $681 |
| Hemoglobin A1C level | 50 | $427 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 12 | $374 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 12 | $373 |
| Thyroid stimulating hormone (TSH) | 19 | $280 |
| COMPREHENSIVE METABOLIC PANEL | 20 | $186 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 14 | $95 |
| Albumin; urine (eg, microalbumin), quantitative | 12 | $61 |
| Creatinine; other source | 12 | $56 |
Drugs they prescribed that Part D paid
$9,395
Pharmacies billed $9,395 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
50 generic and 16 brand-name prescriptions · $9,395 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 66 | 15 | None | 24% | $9,395 |
| 2023 | 555 | 92 | 0% (0) | None | $604,751 |
| 2022 | 1,119 | 149 | None | 13% | $281,394 |
| 2021 | 1,216 | 120 | None | 12% | $129,926 |
| 2020 | 892 | 143 | 3% (26) | 10% | $54,574 |
| 2019 | 259 | 70 | None | 16% | $17,247 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Biktarvy | 34 | $148,665 | $4,373 |
| Triumeq | 19 | $73,103 | $3,848 |
| Symtuza | 14 | $67,219 | $4,801 |
| Genvoya | 13 | $52,486 | $4,037 |
| Juluca | 12 | $42,453 | $3,538 |
| Januvia | 13 | $8,556 | $658 |
| Atorvastatin | 51 | $994 | $19 |
| Gabapentin | 27 | $620 | $23 |
| Metformin | 40 | $593 | $15 |
| Pravastatin | 22 | $567 | $26 |
| Lisinopril | 18 | $471 | $26 |
| Omeprazole | 17 | $470 | $28 |
| Tamsulosin | 39 | $405 | $10 |
| Amlodipine Besylate | 14 | $330 | $24 |
| Hydrochlorothiazide | 14 | $114 | $8 |
2022: 24 drugs
| Jardiance | 16 | $28,275 | $1,767 |
| Januvia | 14 | $22,063 | $1,576 |
| Basaglar Kwikpen U-100 | 11 | $3,797 | $345 |
| Atorvastatin | 144 | $2,785 | $19 |
| Metformin | 86 | $1,065 | $12 |
| Diclofenac | 29 | $996 | $34 |
| Lisinopril | 78 | $889 | $11 |
| Gabapentin | 37 | $817 | $22 |
| Amlodipine Besylate | 64 | $607 | $9 |
| Metoprolol | 19 | $605 | $32 |
| Tamsulosin | 24 | $563 | $23 |
| Baclofen | 12 | $501 | $42 |
| Levothyroxine | 30 | $464 | $15 |
| Glimepiride | 11 | $452 | $41 |
| Carvedilol | 19 | $425 | $22 |
| Losartan | 38 | $391 | $10 |
| Omeprazole | 29 | $387 | $13 |
| Alendronate | 21 | $350 | $17 |
| Hydrochlorothiazide | 39 | $217 | $6 |
| Fluticasone Propionate | 12 | $194 | $16 |
| Glipizide | 15 | $158 | $11 |
| Chlorthalidone | 12 | $126 | $11 |
| Pravastatin | 13 | $118 | $9 |
| Metoprolol | 22 | $110 | $5 |
2021: 29 drugs
| Januvia | 30 | $43,788 | $1,460 |
| Jardiance | 17 | $29,065 | $1,710 |
| Basaglar Kwikpen U-100 | 16 | $5,316 | $332 |
| Atorvastatin | 147 | $2,975 | $20 |
| Gabapentin | 65 | $1,039 | $16 |
| Lisinopril | 82 | $881 | $11 |
| Tamsulosin | 39 | $753 | $19 |
| Amlodipine Besylate | 81 | $707 | $9 |
| Levothyroxine | 27 | $695 | $26 |
| Metformin | 79 | $639 | $8 |
| Diclofenac | 13 | $514 | $40 |
| Carvedilol | 30 | $493 | $16 |
| Cyclobenzaprine | 16 | $478 | $30 |
| Fluticasone Propionate | 36 | $473 | $13 |
| Omeprazole | 30 | $428 | $14 |
| Pravastatin | 14 | $416 | $30 |
| Losartan | 36 | $414 | $12 |
| Alendronate | 28 | $394 | $14 |
| Famotidine | 13 | $300 | $23 |
| Pantoprazole | 11 | $273 | $25 |
| Hydrochlorothiazide | 42 | $261 | $6 |
| Glimepiride | 16 | $227 | $14 |
| Glipizide | 19 | $199 | $10 |
| Metoprolol | 30 | $183 | $6 |
| Simvastatin | 16 | $150 | $9 |
| Benazepril | 16 | $114 | $7 |
| Furosemide | 12 | $94 | $8 |
| Triamcinolone Acetonide | 14 | $65 | $5 |
| Atenolol | 12 | $44 | $4 |
2020: 23 drugs
| Atorvastatin | 75 | $1,342 | $18 |
| Albuterol Sulfate Hfa | 23 | $953 | $41 |
| Cyclobenzaprine | 16 | $555 | $35 |
| Metformin | 65 | $535 | $8 |
| Fluticasone Propionate | 27 | $498 | $18 |
| Lisinopril | 60 | $466 | $8 |
| Diclofenac | 21 | $438 | $21 |
| Pravastatin | 13 | $423 | $33 |
| Amlodipine Besylate | 71 | $422 | $6 |
| Gabapentin | 41 | $370 | $9 |
| Levothyroxine | 12 | $321 | $27 |
| Tamsulosin | 15 | $277 | $18 |
| Hydrocodone-Acetaminophen | 12 | $187 | $16 |
| Losartan | 16 | $168 | $10 |
| Benazepril | 17 | $148 | $9 |
| Omeprazole | 20 | $142 | $7 |
| Hydrochlorothiazide | 26 | $134 | $5 |
| Alendronate | 11 | $127 | $12 |
| Carvedilol | 19 | $126 | $7 |
| Glipizide | 11 | $124 | $11 |
| Simvastatin | 18 | $108 | $6 |
| Metoprolol | 17 | $98 | $6 |
| Ibuprofen | 11 | $51 | $5 |
2019: 5 drugs
| Diclofenac | 12 | $350 | $29 |
| Atorvastatin | 12 | $347 | $29 |
| Benazepril | 15 | $183 | $12 |
| Metformin | 14 | $179 | $13 |
| Amlodipine Besylate | 12 | $115 | $10 |
Money from drug and device companies
$86 in 2025
| 2025 | 3 | 4 | None | $86 |
| 2024 | 1 | 1 | None | $74 |
| 2023 | 3 | 3 | None | $171 |
| 2022 | 3 | 3 | None | $120 |
| 2021 | 1 | 4 | None | $169 |
| 2019 | 1 | 1 | None | $13 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| PolyNovo North America | Novosorb Btm | $59 | 2 payments
|
| Indivior | Sublocade | $14 | 1 payment
|
| Pfizer | Prevnar 20 | $13 | 1 payment
|
See all 4 published payments
| Indivior | Meals · 2025-09-17 | Sublocade | $14 |
| PolyNovo North America | Meals · 2025-07-31 | Novosorb Btm | $29 |
| Pfizer | Meals · 2025-06-01 | Prevnar 20 | $13 |
| PolyNovo North America | Meals · 2025-05-01 | Novosorb Btm | $30 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $74
| Lilly USA | Mounjaro | $74 | 1 payment
|
2023: $171
| GlaxoSmithKline | Shingrix | $104 | 1 payment
|
| Gilead Sciences | Epclusa | $49 | 1 payment
|
| Merck Sharp & Dohme | Pifeltro | $18 | 1 payment
|
2022: $120
| Lilly USA | Mounjaro | $90 | 1 payment
|
| ViiV Healthcare | Apretude | $18 | 1 payment
|
| EMD Serono | None | $12 | 1 payment
|
2021: $169
| Novo Nordisk | Ozempic | $169 | 4 payments
|
2019: $13
| Merck Sharp & Dohme | Nexplanon | $13 | 1 payment
|
Professional record
- NPI
- 1558724963
- Licence
- CA A159093California A159093: Current · expires 2028-10-31
- Group
- Clinica Sierra Vista
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 625 34th St Ste 100&200, Bakersfield, CA, 93301
- NPI first listed
- 2016-04-02
- NPI last updated
- 2025-04-17
- NPI record certified
- 2025-04-17
This is when the NPI record was last certified, not a medical board exam.